Correction to: Efficacy of Radiofrequency Ablation in Patients with Metastatic Liver Tumors from Breast Carcinoma

Zahra Mardanshahi 1,
Yaghob Sakhaeei 2,
Mohammad Khademloo 3,
Gahsem Janbabai 4,
Seyed Ghader Aghili 5,
Maryam Tayebi 6

1 Assistant Professor, Department of Radiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2 Assistant Professor, Department of Radiology, Faculty of Medicine, Islamic Azad University, Sari Branch, Mazandaran, Sari, Iran
3 Associate Professor, Department of Community Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4 Associate Professor, Department of Oncology, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
5 Radiologist, Department of Radiology, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran
6 MSc in Medical Imaging, Department of Radiology, Sari Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

In the article published in Volume 27, issue 158, 2017, the Results section in English Abstract have been published incorrectly. The correct Results is given below:

Results: The most frequent sizes of mass were 2-4 cm (n=33, 54%) and 4-5 cm (n=23, 38%). Among the patients, 35 (67.3%) had one tumor before, in 11.5% renew tumor happened, and 65.4% had one tumor after treatment. Liver tumors were controlled in 76.9% in case group which was statistically higher than that in control group (P< 0.0001).

اصلاحی: بررسی تأثیر درمانی امواج رادیو فرکوئنسی در بیماران با تومورهای متاستاتیک کبد با منشا پستان

Zehra Mardanshahi
Yaqub Sabeti
Mohammad Khadem
Qasem Jan Babi
Sadeq Qadri
Mehran Teby

E-mail: zmardanshahi@yahoo.com

متن به فارسی:

در مقاله فوق که در شماره 158 اسفند 1396 در دوره 27 این تشریح شده بود، قسمت Result در جمله انگلیسی اشتباه چاپ شده بود و به صورت زیر اصلاح شد:

Results: The most frequent sizes of mass were 2-4 cm (n=33, 54%) and 4-5 cm (n=23, 38%). Among the patients, 35 (67.3%) had one tumor before, in 11.5% renew tumor happened, and 65.4% had one tumor after treatment. Liver tumors were controlled in 76.9% in case group which was statistically higher than that in control group (P< 0.0001).